General Clinical Chemistry Analyzers and Accessories
Abcam TW-37, 10MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CCT128930, 50MG
MW 341.8 Da, Purity =98%. Potent and selective AKT2 inhibitor (IC50= 6 nM) with selectivity greater than 28-fold and 20-fold over PKA kinase (IC50= 168 nM) and p70S6K (IC50= 120 nM), respectively.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Bafetinib (INNO-406).
Bafetinib (INNO-406).
The product is subject to the following: Abcam Restricted Use Statement
Abcam TW-37, 100MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ISX 9, neurogenic agent.
ISX 9, neurogenic agent.
The product is subject to the following: Abcam Restricted Use Statement
Abcam YM-155, survivin inhibitor, 25MG
MW 443.3 Da, Purity >98%. Novel small molecule potent survivin suppressant. Inhibits survivin promoter activity (IC₅₀ = 0.54 nM) and down-regulates survivin in vitro and in vivo. Induces apoptosis in human tumor cell lines in vitro at 10 nM, with little effect on other IAP or Bcl-2 family members.
The product is subject to the following: Abcam Restricted Use Statement
Abcam YM-155, survivin inhibitor, 5MG
MW 443.3 Da, Purity >98%. Novel small molecule potent survivin suppressant. Inhibits survivin promoter activity (IC₅₀ = 0.54 nM) and down-regulates survivin in vitro and in vivo. Induces apoptosis in human tumor cell lines in vitro at 10 nM, with little effect on other IAP or Bcl-2 family members.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 4'-hydro x yazobenzene-2-carbo x ylic acid (HABA), 1G
MW 242.23 Da. An endogenous metabolite. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZ-20, 5MG
MW 412.5 Da. Potent and selective ATR kinase inhibitor (IC₅₀ = 5 nM in vitro; IC₅₀ = 50 nM in carcinoma cell lines). Selective versus mTOR (8-fold). Displayed selectivity versus a panel of 442 kinases.Inhibits LoVo colorectal adenocarcinoma tumor cell growth.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SRT1720 hydrochloride, 5MG
MW 506 Da, Purity >=98%. Selective SIRT1 activator (EC₅₀ = 0.16 μM), 230-fold less potent for SIRT2 and SIRT3. Induce autophagy.
The product is subject to the following: Abcam Restricted Use Statement
Abcam 2', 7'-Dichlorofluorescein di-ß-D-lactoside, 5MG
MW 1049.76 g/mol. Highly sensitive fluorescent substrate for measuring beta-lactosidase and glucosidase inside live cells. Retains fluorescence at low pH due to lower pKa than comparable fluorophores. Suitable for measuring activity in the acidic lysosome environment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam CHIR-124, 50MG
MW 419.9 Da, Purity >98%. Novel and potent Chk1 inhibitor (IC₅₀ = 0.3 nM), 2,000-fold more potent than Chk2 (IC₅₀ = 0.7 μM). Also, potently targets other kinases such as FLT3 (IC₅₀ = 5.8 nM), PDGFR (IC₅₀ = 6.6 nM), GSK-3 (IC₅₀ = 23.3 nM) and Fyn (IC₅₀ = 98.8 nM) .
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2940680 (Taladegib), 50MG
MW 512.5 Da. Potent Hedgehog signaling pathway inhibitor. Smoothened antagonist. Inhibits growth of cancer cell lines containing a disease-relevant Smoothened gene mutation. Has anti-tumor activity in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LMK 235, HDAC inhibitor, 25MG
MW 294.35 Da, Purity >98%. Highly potent and selective HDAC inhibitor. Greater potency for HDAC4 and HDAC5 (IC₅₀ = 11.9 and 4.2 nM, respectively) than other HDAC family members (IC₅₀ values = HDAC1 320 nM, HDAC2 881 nM, HDAC6 55.7 nM, and HDAC8 1278 nM. Demonstrates inhibitor activity in human ovarian cell lines (IC₅₀ =0.49μM) and cisplatin resistant cell lines (IC₅₀ = 0.32μM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SIS3, Smad3 inhibitor, 5MG
MW 490 Da, Purity >98%. Potent and selective Smad3 inhibitor. Selectively inhibits TGF-beta 1/ALK5-induced Smad3 phosphorylation. Inhibits the TGF-beta 1 effect on type I procollagen expression at the transcriptional levels via the Smad3-binding site. Has no effect on Smad2, p38, MAPK, ERK or PI 3-kinase signaling.
The product is subject to the following: Abcam Restricted Use Statement